New Study Finds More Than 60% of Adult Women in the U.S. Experience Urinary Incontinence

IRVINE, Calif.–(BUSINESS WIRE)–Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today highlighted the publication of a new study that provides updated estimates of urinary incontinence (UI) prevalence in the U.S.

The study, titled “Updated Prevalence of Urinary Incontinence in Women: 2015-2018 National Population-Based Survey Data,” was published in the peer-reviewed journal Female Pelvic Medicine & Reconstructive Surgery, the official journal of the American Urogynecologic Society (AUGS).

Study authors at the University of Wisconsin School of Medicine and Public Health utilized publicly available data from the 2015-2018 National Health and Nutrition Examination Survey (NHANES) sample and included over 5,000 women who completed mobile examinations and computer-assisted personal interviews with standardized UI questions.

Key findings of the study include:

• The overall prevalence of UI in adult U.S. women 20 years and older is approximately 62%, or more than 78 million women.
  • This is an increase from prior prevalence estimates (38%-53%) using NHANES data from 1999-2016.
  • 28 million, or approximately 22% of adult U.S. women experience moderate or more severe UI.
• Of those with UI, 38% had stress urinary incontinence, 22% had urgency urinary incontinence, 31% had mixed urinary incontinence (stress and urgency), and 9% had unspecified incontinence.
• Increases in UI prevalence may be related to population aging and increasing rates of obesity (body mass index >40). These factors and vaginal birth had the strongest association with UI.
• The substantial prevalence of UI reinforces that routine screening for UI should be included as part of preventive care for all women.

“We thought it was really important to do this research because incontinence is such a growing and undertreated condition,” said Heidi W. Brown, M.D., lead author of the study and assistant professor of female pelvic medicine and reconstructive surgery at the University of Wisconsin School of Medicine and Public Health. “As urogynecologists, we talk to women about bladder and bowel problems every day, so we know how common incontinence is, how significantly it impacts women’s daily lives, and see more and more women being impacted as the population ages. Our goal with this research was to use data from a rigorous, trusted source to increase awareness about how common incontinence is and disrupt the taboo of talking about it. Our hope is that making these data available to physicians and the public will help more women start the conversation about solutions earlier.”

Raymond W. Cohen, chief executive officer of Axonics, said, “This study is further evidence that the number of women in the U.S. with UI is in the tens of millions and growing. Our mission at Axonics is to provide meaningful solutions to improve the quality of life of adults with these conditions. Our rechargeable sacral neuromodulation system and Bulkamid^® have been used to provide safe, efficacious, and long-lasting symptom relief to tens of thousands of UI patients since their introduction. As part of our commitment to clinicians and their patients, we will be launching a national television direct-to-consumer advertising campaign in the coming months to continue to raise awareness of UI and Axonics therapies to treat all forms of incontinence.”

About Axonics

Based in Irvine, Calif., Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 1 on the 2021 Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America.

The company’s rechargeable sacral neuromodulation (SNM) system provides patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, Axonics’ best-in-class urethral bulking agent, Bulkamid^®, provides safe and durable symptom relief to women with stress urinary incontinence (SUI). Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. SUI affects an estimated 29 million women in the U.S. alone. Axonics’ clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com.

Contacts

Axonics contact:

Neil Bhalodkar

Investor Relations

949-336-5293

[email protected]